Abeona Therapeutics Inc. ABEO
Abeona Therapeutics Inc. (Nasdaq: ABEO) is a rare genetic drug developer. Its lead program, ZEVASKYN (prademagene zamikeracel), is in Pre-clinical for Wounds in recessive dystrophic epidermolysis bullosa (RDEB).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ZEVASKYN (prademagene zamikeracel) | RDEB wounds | gene therapy | Approved |
| ABO-701 (PSMA-SIR-T) | PSMA-expressing solid tumors | cell therapy | Pre-clinical |
| AIM capsid AAV ophthalmic gene therapies | ophthalmic diseases | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical rare genetic companies
- Niagen Bioscience, Inc. Unknown
- Korro Bio, Inc. KRRO
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.